Comparison Overview

Keystone Industries

VS

PT Kalbe Farma, Tbk

Keystone Industries

480 S. Democrat Rd, Gibbstown, New Jersey, 08027, US
Last Update: 2025-05-06 (UTC)
View Profile
Between 750 and 799
http://www.keystoneindustries.com

Keystone Industries combines reliability, flexibility, and innovation in manufacturing and R&D. We are committed to the goal of total customer satisfaction. We are dedicated to the achievement of this goal by meeting or exceeding our customer expectations for product quality, competitive pricing and prompt delivery and customer service. Serving the Cosmetics, Dental, and health industries, we bring over 100 years of manufacturing expertise to your project.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 279
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

PT Kalbe Farma, Tbk

KALBE Building, Jakarta, DKI Jakarta, 10510, ID
Last Update: 2025-03-16 (UTC)
Between 750 and 799
http://www.kalbe.co.id/

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

NAICS: 325
NAICS Definition:
Employees: 11,705
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/keystone-industries.jpeg
Keystone Industries
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/pt-kalbe-farma.jpeg
PT Kalbe Farma, Tbk
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Keystone Industries
100%
Compliance Rate
0/4 Standards Verified
PT Kalbe Farma, Tbk
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Keystone Industries in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for PT Kalbe Farma, Tbk in 2025.

Incident History — Keystone Industries (X = Date, Y = Severity)

Keystone Industries cyber incidents detection timeline including parent company and subsidiaries

Incident History — PT Kalbe Farma, Tbk (X = Date, Y = Severity)

PT Kalbe Farma, Tbk cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/keystone-industries.jpeg
Keystone Industries
Incidents

No Incident

https://images.rankiteo.com/companyimages/pt-kalbe-farma.jpeg
PT Kalbe Farma, Tbk
Incidents

No Incident

FAQ

PT Kalbe Farma, Tbk company demonstrates a stronger AI Cybersecurity Score compared to Keystone Industries company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, PT Kalbe Farma, Tbk company has disclosed a higher number of cyber incidents compared to Keystone Industries company.

In the current year, PT Kalbe Farma, Tbk company and Keystone Industries company have not reported any cyber incidents.

Neither PT Kalbe Farma, Tbk company nor Keystone Industries company has reported experiencing a ransomware attack publicly.

Neither PT Kalbe Farma, Tbk company nor Keystone Industries company has reported experiencing a data breach publicly.

Neither PT Kalbe Farma, Tbk company nor Keystone Industries company has reported experiencing targeted cyberattacks publicly.

Neither Keystone Industries company nor PT Kalbe Farma, Tbk company has reported experiencing or disclosing vulnerabilities publicly.

Neither Keystone Industries nor PT Kalbe Farma, Tbk holds any compliance certifications.

Neither company holds any compliance certifications.

PT Kalbe Farma, Tbk company has more subsidiaries worldwide compared to Keystone Industries company.

PT Kalbe Farma, Tbk company employs more people globally than Keystone Industries company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Keystone Industries nor PT Kalbe Farma, Tbk holds SOC 2 Type 1 certification.

Neither Keystone Industries nor PT Kalbe Farma, Tbk holds SOC 2 Type 2 certification.

Neither Keystone Industries nor PT Kalbe Farma, Tbk holds ISO 27001 certification.

Neither Keystone Industries nor PT Kalbe Farma, Tbk holds PCI DSS certification.

Neither Keystone Industries nor PT Kalbe Farma, Tbk holds HIPAA certification.

Neither Keystone Industries nor PT Kalbe Farma, Tbk holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
References
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References